Year: 2025
Type: article
Abstract: In this review, the synergistic application strategy and technological breakthrough of new generation vaccine technology and immune checkpoint inhibitor were discussed. Combined vaccine therapy with immune checkpoint inhibitors targeting PD-1/CTLA-4 can effectively reverse T cell depletion and enhance anti-tumor immune response. For the clinical translation bottlenecks of personalized vaccines (such as patient-specific antigen synthesis and resource-intensive GMP production), the automated platforms (such as BioNTech's "RNA printer") and the universal vaccine strategies targeting conserved neoantigens (such as KRAS G12D or HPV E6/E7 virus antigens) significantly increase the scalability. The technical innovations highlighted include: 1) CRISPR-Cas9 enhances antigen presentation by editing dendritic cells (DCs) or knocks out immunosuppressive genes such as PD-L1; 2) The AI-driven platform optimizes the prediction of antigen-adjuvant combination and dosing scheme design through algorithms. These technological advances provide multi-dimensional solutions for precision immunotherapy, and promote the development of cancer vaccines in the direction of high efficiency and intelligence.
Source: Theoretical and Natural Science
Author: Siying Li
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4410417941